From GlobeNewswire: 2025-06-15 10:45:00

Intellia Therapeutics announced promising three-year follow-up data from Phase 1 of lonvo-z study, showing 98% reduction in HAE attacks. All 10 patients were attack-free and treatment-free for a median of 23 months. Phase 3 HAELO trial is ahead of schedule and over half of patients were screened in the U.S. Lonvo-z was well tolerated with a favorable safety profile. Lonvo-z has potential to be the first one-time therapy for most HAE patients. Intellia plans to provide updates on enrollment and submit a biologics license application in 2026 for a U.S. launch in 2027.



Read more at GlobeNewswire: Intellia Therapeutics Announces Positive Three-Year Data